Related Experiment Video
Updated: Jul 16, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Targeting hepatic cholesterol sensing to tackle metabolic dysfunction-associated steatohepatitis
Mengwei Zang1,2,3, Yu Li4
1Barshop Institute for Longevity and Aging Studies, Center for Healthy Aging, and.
The Journal of Clinical Investigation
|July 15, 2026
Summary
Nuclear factor erythroid 2-related factor 1 (NFE2L1) regulates cholesterol sensing and VLDL export in metabolic dysfunction-associated steatohepatitis (MASH). Targeting NFE2L1 may offer therapeutic benefits for MASH by modulating lipid homeostasis.
Area of Science:
- Hepatology
- Metabolic Diseases
- Molecular Biology
Background:
- Metabolic dysfunction-associated steatohepatitis (MASH) affects a significant global population, with incompletely understood mechanisms.
- Cholesterol overload is a recognized key driver of MASH pathogenesis.
- Targeting cholesterol sensing pathways presents a potential therapeutic strategy for MASH.
Purpose of the Study:
- To identify key regulators linking cholesterol sensing to very-low-density lipoprotein (VLDL)-mediated lipid export in hepatocytes.
- To elucidate the molecular mechanism by which nuclear factor erythroid 2-related factor 1 (NFE2L1) influences hepatic lipid homeostasis.
Main Methods:
- Investigated the interaction between NFE2L1 and insulin-induced gene 1 (INSIG1) in hepatocytes.
- Assessed the impact of NFE2L1 on INSIG1 degradation and SREBP activation.
- Evaluated the effect of hepatic NFE2L1 overexpression on MASH progression in a preclinical model.
Main Results:
- NFE2L1 was identified as a critical regulator connecting cholesterol sensing to VLDL export.
- NFE2L1 interacts with and promotes the degradation of INSIG1 in a cholesterol-dependent manner.
- Hepatic NFE2L1 overexpression reduced INSIG1 levels and ameliorated MASH progression.
Conclusions:
- The NFE2L1-INSIG1 interaction is crucial for maintaining hepatic and systemic lipid homeostasis through SREBP activation and VLDL secretion.
- NFE2L1 plays a significant role in regulating lipid metabolism and MASH pathogenesis.
- Targeting NFE2L1 demonstrates therapeutic potential for ameliorating MASH.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...